Glaukos Corporation (GKOS) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Devices Branche. Der Hauptsitz des Unternehmens ist in Aliso Viejo, CA, United States. Der aktuelle CEO ist Thomas William Burns.
GKOS hat IPO-Datum 2015-06-25, 995 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $7B.
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company headquartered in San Clemente, California, specializing in innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company's flagship products include the iStent family of micro-bypass stents—iStent, iStent inject, and iStent inject W—which are implanted during cataract surgery to improve aqueous humor outflow and treat mild-to-moderate open-angle glaucoma. Its pipeline includes iStent Infinite, a three-stent system designed for standalone use in refractory glaucoma patients, and iDose TR, a targeted injectable implant that delivers therapeutic medication levels. Glaukos markets its products globally through a combination of direct sales operations and distributor networks. Founded in 1998, the company continues to advance minimally invasive surgical solutions for serious eye conditions.
